Latest

Mar 24, 2016
Several factors are combining to change the definition of what healthcare truly is, and how it will be delivered and experienced in the next few years.
Mar 23, 2016
Just as insurers and regulators have sought to tamp down compounding costs and utilization, observers are acknowledging that the practice may be an antidote to spiraling drug prices. John S. Linehan reports.
Mar 18, 2016
Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.
Mar 10, 2016
Elvis Pacelat asks why the prospect of harmonized content is so challenging, and what can pharma companies learn from other sectors about more optimal, modern ways of working and sharing data?
Mar 08, 2016
Pharmaceutical Executive
As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development, writes Clara Heering.
Mar 06, 2016
Pharmaceutical Executive
Can novel drug delivery technologies offering options beyond the traditional tablet or syringe transform the therapeutic experience for patients?
Mar 03, 2016
Clinical trials are challenging because pain is subjective, making it hard to define objective endpoints or to compare one drug to another.
Mar 01, 2016
Bruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.
Feb 29, 2016
Anti-corruption NGO Transparency International now has pharma in its sights. Pharm Exec speaks to TI's Sophie Peresson.
Feb 26, 2016
FDA needs to make major changes in how it evaluates R&D of new combination therapies for cancer and other serious conditions, say patient advocates, cancer specialists and biopharma companies.
native1_300x100
lorem ipsum